Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) provides access to the company’s official regulatory disclosures as a clinical-stage TechBio and biotechnology issuer. These documents offer detailed information about Recursion’s financial condition, governance, capital markets activity and key corporate events related to its Recursion OS platform and drug development programs.
Investors can review current reports on Form 8-K, where Recursion reports material events such as quarterly financial results, leadership transitions, collaboration milestones and equity issuances. Recent 8-K filings describe items including second and third quarter financial results, the appointment of a new Chief Executive Officer and President with the prior CEO becoming Chair of the Board, milestone payments from collaborations, and unregistered sales of equity securities connected to acquisitions and license arrangements.
Through its registration statements and prospectus supplements filed under its automatic shelf registration on Form S-3ASR, Recursion documents offerings and resale registrations for shares issued in connection with agreements such as a master license with Tempus AI, Inc. and a membership interest purchase agreement involving a joint venture for an ENPP1 program. These filings outline the number of shares involved, transaction structure and reliance on exemptions from registration for initial issuances.
Users of this page can also monitor filings related to corporate governance and stockholder matters, such as annual meeting results and advisory votes, as well as information about independent auditor ratification. Together with annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible through EDGAR, these filings form a comprehensive record of RXRX’s regulatory history.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of key filings. This helps readers quickly interpret lengthy documents such as 10-K and 10-Q reports, understand the implications of Form 8-K disclosures, and track any insider-related or equity issuance activity that may be relevant when evaluating Recursion Pharmaceuticals.
RXRX filed a Form 144 reporting proposed sales of Class A founder shares.
The filing lists four sales of 40,000 Class A shares on 01/05/2026, 01/20/2026, 02/04/2026, and 02/19/2026 with proceeds of $170,000, $178,800, $164,800, and $138,400, respectively.
Recursion Pharmaceuticals Chief Financial Officer Ben R. Taylor reported routine share movements in company stock. On March 17, 2026, he completed an open-market sale of 7,956 shares of Class A Common Stock at $3.39 per share. On March 16, 2026, 7,075 shares were disposed to cover tax obligations tied to net settlement of restricted stock units, which is not an open-market trade. After these transactions, Taylor directly held 1,180,318 shares of Class A Common Stock. The open-market sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2025, indicating the timing was planned in advance.
RXRX submitted a Form 144 reporting the proposed sale of 7,956 Class A shares tied to restricted stock vesting on 03/15/2026. The filing lists prior dispositions by Ben Taylor of 21,383 Class A shares on 12/29/2025 and 13,426 Class A shares on 02/18/2026. The broker listed is Fidelity Brokerage Services LLC.
Recursion Pharmaceuticals director Christopher Gibson converted 20,000 shares of Class B Common Stock into 20,000 shares of Class A Common Stock on March 9, 2026. The conversion price was reported as $0.00 per share.
On the same date, he made a bona fide gift of 20,000 Class A shares, leaving him with 906,556 Class A shares directly owned and 4,523,334 Class B shares directly owned after these transactions.
RECURSION PHARMACEUTICALS, INC. CEO and President Najat Khan reported an open-market sale of 28,298 shares of Class A common stock on March 9, 2026 at a weighted average price of $3.3451 per share. The trades were executed at prices ranging from $3.32 to $3.405.
After this transaction, Khan directly holds 2,262,085 shares of Class A common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025, indicating the timing was set in advance rather than decided opportunistically.
Recursion Pharmaceuticals reported an insider transaction: Najat Khan sold 124,403 common shares on 12/22/2025 for $548,587.96. The filing also lists a planned equity compensation sale of 28,298 common shares dated 02/15/2026. The report is a Form 144 disclosure of resale activity.
Recursion Pharmaceuticals director Blake Borgeson sold shares in an open-market transaction. On 2026-03-03, he sold 170,000 shares of Class A common stock at an average price of $3.46 per share. After this sale, he directly owns 6,259,863 shares of the company’s Class A common stock.
RXRX Form 144 notice reports two block sales of Class A shares by Blake Borgeson. The filing lists a sale on 01/06/2026 of 220,000 Class A shares for $959,200 and a sale on 02/03/2026 of 220,000 Class A shares for $924,000.
The filing also lists earlier issuer-designated Class A founder/compensation share entries dated 09/01/2016 (110,000) and 09/01/2017 (60,000).
Recursion Pharmaceuticals filed a prospectus supplement establishing an at-the-market offering to sell shares of its Class A Common Stock having an aggregate offering price of up to $300,000,000. Sales may be made from time to time through TD Securities (USA) LLC (TD Cowen) as agent or principal.
The prospectus states the offering may include negotiated transactions, block trades or any method permitted by law and that TD Cowen may receive compensation up to 3% of gross proceeds. The last reported sale price of the Class A Common Stock was $3.53 per share on February 24, 2026. The prospectus illustration assumes sale of 84,985,835 shares for aggregate proceeds of $300,000,000, resulting in up to 606,816,881 shares outstanding (based on 521,831,046 shares outstanding as of December 31, 2025).
Recursion Pharmaceuticals’ annual report shows a fast‑growing AI‑driven drug platform, expanding pipeline, and widening losses as it invests heavily in R&D. Revenue rose to $74.7M in 2025, mainly from partnerships such as Sanofi and Roche, while net loss increased to $644.8M as research and development spending reached $475.3M.
The company ended 2025 with $753.9M in cash, cash equivalents, and restricted cash after multiple equity raises and collaboration milestones. Management highlights its first AI‑enabled clinical proof of concept in familial adenomatous polyposis, five clinical programs, and more than $500M in cumulative partner payments, but notes it expects continued losses and future capital needs.